Cannabinoids inhibit fibrogenesis in diffuse systemic sclerosis fibroblasts
Open Access
- 9 July 2009
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 48 (9), 1050-1056
- https://doi.org/10.1093/rheumatology/kep189
Abstract
Objective. It has been demonstrated that the endocannabinoid system is up-regulated in pathologic fibrosis and that modulation of the cannabinoid receptors might limit the progression of uncontrolled fibrogenesis. The aim of this study was to investigate whether the synthetic cannabinoid receptor agonist WIN55,212-2 could modulate fibrogenesis in an in vitro model of dcSSc. Methods. The expression of cannabinoid receptors CB1 and CB2 was assessed in dcSSc fibroblasts and healthy control fibroblasts. To investigate the effect of WIN55,212-2 on dcSSc fibrogenesis, we studied type I collagen, profibrotic cytokines, fibroblast transdifferentiation into myofibroblasts, apoptotic processes and activation of the extracellular signal-related kinase 1/2 pathway prior to and after the treatment with the synthetic cannabinoid at increasing concentrations. Results. Both CB1 and CB2 receptors were over-expressed in dcSSc fibroblasts compared with healthy controls. WIN55,212-2 caused a reduction in extracellular matrix deposition and counteracted several behavioural abnormalities of scleroderma fibroblasts including transdifferentiation into myofibroblasts and resistance to apoptosis. The anti-fibrogenic effect of WIN55,212-2 was not reverted by selective cannabinoid antagonists. Conclusions. Our preliminary findings suggest that cannabinoids are provided with an anti-fibrotic activity, thereby possibly representing a new class of agents targeting fibrosis diseases.Keywords
This publication has 33 references indexed in Scilit:
- Cannabinoid Receptors: Where They are and What They doJournal of Neuroendocrinology, 2008
- GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M currentProceedings of the National Academy of Sciences of the United States of America, 2008
- Cannabinoids: A New Group of Agonists of PPARsPPAR Research, 2007
- The cannabinoid WIN 55,212-2 inhibits transient receptor potential vanilloid 1 (TRPV1) and evokes peripheral antihyperalgesia via calcineurinProceedings of the National Academy of Sciences of the United States of America, 2006
- CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosisNature Medicine, 2006
- Receptor-Independent Effects of Endocannabinoids on Ion ChannelsCurrent Pharmaceutical Design, 2006
- Cannabinoid-based drugs as anti-inflammatory therapeuticsNature Reviews Immunology, 2005
- Prospects for cannabinoids as anti‐inflammatory agentsJournal of Cellular Biochemistry, 2002
- Molecular characterization of a peripheral receptor for cannabinoidsNature, 1993
- Structure of a cannabinoid receptor and functional expression of the cloned cDNANature, 1990